Phase 2 obesity trial
- Reported quantity
- 3.0, 4.5 and 6.0 mg maintenance after stepwise escalation
- Frequency
- Once weekly
- Study duration
- 24 weeks
Escalation from a low starting quantity over several weeks was part of every arm.
Protocols · Metabolic
Mazdutide: literature-reported ranges
Mazdutide is an oxyntomodulin-derived dual GLP-1/glucagon receptor agonist developed largely through Chinese phase 2 and phase 3 programmes in obesity and type 2 diabetes. The reported figures below come from those registered protocols.
Read this first
Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.
Compound at a glance
- Class
- GLP-1 receptor / glucagon receptor dual agonist (oxyntomodulin analogue)
- Reported half-life
- Supports once-weekly administration in published trial protocols
- Routes used in the literature
- Subcutaneous in registered trials
- Also written as
- IBI362, LY3305677
What the published studies reported
Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.
Phase 3 type 2 diabetes programme
- Reported quantity
- 4.0 mg and 6.0 mg maintenance arms
- Frequency
- Once weekly
- Study duration
- 48 weeks
HbA1c and body weight were the co-reported endpoints.
Mixed with 3 ml of bacteriostatic water
The same arithmetic for every vial size Mazdutide is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.
Mazdutide · 3 ml bacteriostatic water
| Vial size | Concentration | Per 1 unit |
|---|---|---|
| 5 mg | 1.67 mg/ml | 17 mcg |
| 10 mg | 3.33 mg/ml | 33 mcg |
No single reported amount applies to this compound, so only the concentration and the value of one unit are shown. Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.
Reconstitution maths
Supplied as 5 mg and 10 mg lyophilised vials. A 10 mg vial in 3 ml of bacteriostatic water gives 3.33 mg/ml, so one U-100 unit carries 33.3 mcg.
Open the reconstitution calculatorHow to read these figures
- Reported maintenance quantities are the endpoint of a multi-week escalation, not an entry figure.
- Most of the trial record is in Chinese populations; generalisation is a documented limitation.
- Investigational compound with no marketing authorisation in the UK, EU or US.
Sources and citations
No peer-reviewed primary literature reporting administered quantities exists for this item. Anything circulating online about quantities is anecdote rather than evidence, and this page will not reproduce it. The database links below are kept so you can check for yourself as new work is published.
Search the databases yourself
Other metabolic compounds
AdipotidePro-apoptotic peptidomimetic targeting prohibitin in white adipose vasculatureAICARAMP analogue and AMPK activator (small molecule, not a peptide)CagrilintideLong-acting amylin analogue (AMY1 class)GLP1 (semaglutide / Ozempic)GLP-1 receptor agonist
All research protocolsPeptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.